Pfizer Ltd
NSE:PFIZER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pfizer Ltd
Cash from Financing Activities
Pfizer Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Pfizer Ltd
NSE:PFIZER
|
Cash from Financing Activities
-₹8B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Financing Activities
-₹13.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Financing Activities
-₹14.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Financing Activities
-₹17.5B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Financing Activities
₹14.5B
|
CAGR 3-Years
103%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Financing Activities
-₹19.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Pfizer Ltd
Glance View
Pfizer Ltd., a giant in the pharmaceutical industry, has woven its identity deeply into the fabric of healthcare innovation. Established initially to create chemical compounds, it evolved into a pharmaceutical pioneer through a series of strategic developments and acquisitions. Headquartered in New York, the company has a sprawling international presence, with an intricate network of research facilities, manufacturing plants, and marketing offices spread across the globe. This global footprint empowers Pfizer to leverage diverse talent and resources, driving innovation and efficiency. At the core of Pfizer’s operations is its research and development engine, a crucial element that churns out new medicines and therapies. By investing heavily in R&D, absorbing over $8 billion annually, the company relentlessly pursues breakthroughs in areas such as oncology, vaccines, rare diseases, and primary care, consistently bringing advanced treatments from laboratories to clinics. The way Pfizer sustains its financial health is as much about strategic foresight as it is about scientific prowess. Its revenue streams are crafted through a mix of patent-protected pharmaceuticals, consumer health products, and vaccines. The blockbuster drug era, epitomized by the success of Lipitor, showcased its capability to capture market leadership efficiently. More recently, Pfizer's collaboration with BioNTech on the COVID-19 vaccine highlighted its agility and strategic partnerships. Such initiatives solidify its position in the market and open lucrative opportunities. Beyond products, Pfizer employs a robust marketing strategy and leverages an extensive distribution network to ensure these innovations reach a global clientele efficiently. Through a combination of smart financial management, cutting-edge research, and decisive partnerships, Pfizer Ltd. has positioned itself as a towering figure in the pharmaceutical landscape, capable of responding to global health challenges while ensuring sustainable growth.
See Also
What is Pfizer Ltd's Cash from Financing Activities?
Cash from Financing Activities
-8B
INR
Based on the financial report for Dec 31, 2025, Pfizer Ltd's Cash from Financing Activities amounts to -8B INR.
What is Pfizer Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
13%
Over the last year, the Cash from Financing Activities growth was -283%. The average annual Cash from Financing Activities growth rates for Pfizer Ltd have been -34% over the past three years , 13% over the past five years .